Valgenesis Portugal, Lda
Valgenesis Portugal, Lda.
PDA J Pharm Sci Technol. 2024 Oct 22;78(5):604-612. doi: 10.5731/pdajpst.2023.012922.
The pursuit of harnessing data for knowledge creation has been an enduring quest, with the advent of machine learning (ML) and artificial intelligence (AI) marking significant milestones in this journey. ML, a subset of AI, emerged as the practice of employing mathematical models to enable computers to learn and improve autonomously based on their experiences. In the pharmaceutical and biopharmaceutical sectors, a significant portion of manufacturing data remains untapped or insufficient for practical use. Recognizing the potential advantages of leveraging the available data for process design and optimization, manufacturers face the daunting challenge of data utilization. Diverse proprietary data formats and parallel data generation systems compound the complexity. The transition to Pharma 4.0 necessitates a paradigm shift in data capture, storage, and accessibility for manufacturing and process operations. This paper highlights the pivotal role of AI in converting process data into actionable knowledge to support critical functions throughout the whole product life cycle. Furthermore, it underscores the importance of maintaining compliance with data integrity guidelines, as mandated by regulatory bodies globally. Embracing AI-driven transformations is a crucial step toward shaping the future of the pharmaceutical industry, ensuring its competitiveness and resilience in an evolving landscape.
利用数据进行知识创造一直是人们不懈的追求,机器学习(ML)和人工智能(AI)的出现标志着这一旅程中的重要里程碑。ML 是 AI 的一个子集,它是指运用数学模型使计算机能够根据经验自主学习和改进的实践。在制药和生物制药领域,大量的制造数据尚未被利用或不足以实际使用。制造商认识到利用可用数据进行工艺设计和优化的潜在优势,但面临着数据利用的艰巨挑战。不同的专有数据格式和并行数据生成系统增加了复杂性。向 Pharma 4.0 的转变需要在数据捕获、存储和制造及工艺操作的可访问性方面进行范式转变。本文强调了 AI 在将工艺数据转化为可操作的知识以支持整个产品生命周期的关键功能方面的关键作用。此外,它还强调了遵守全球监管机构规定的数据完整性准则的重要性。采用 AI 驱动的转型是塑造制药行业未来的关键一步,确保其在不断变化的环境中具有竞争力和弹性。